

Winfried F Pickl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7386739/publications.pdf>

Version: 2024-02-01

109
papers

4,494
citations

147801

31
h-index

114465

63
g-index

111
all docs

111
docs citations

111
times ranked

8607
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	2.9	766
2	Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. Journal of Immunology, 1996, 157, 3850-9.	0.8	283
3	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications, 2019, 10, 4186.	12.8	236
4	Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains. Journal of Immunology, 2004, 172, 2352-2359.	0.8	228
5	Neutrophil Granulocyte-committed Cells Can Be Driven to Acquire Dendritic Cell Characteristics. Journal of Experimental Medicine, 1998, 187, 1019-1028.	8.5	182
6	Lipid Rafts and Pseudotyping. Journal of Virology, 2001, 75, 7175-7183.	3.4	149
7	Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB Journal, 2012, 26, 2253-2276.	0.5	144
8	SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 ⁺ T cell responses. Science Immunology, 2021, 6, .	11.9	143
9	Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by IL-21 deficiency. Journal of Allergy and Clinical Immunology, 2014, 133, 1651-1659.e12.	2.9	124
10	Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nature Communications, 2014, 5, 5360.	12.8	116
11	RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. Nature Immunology, 2016, 17, 1352-1360.	14.5	115
12	Azithromycin suppresses CD4+ T-cell activation by direct modulation of mTOR activity. Scientific Reports, 2014, 4, 7438.	3.3	90
13	The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. European Journal of Immunology, 2008, 38, 2678-2688.	2.9	86
14	Molecular Aspects of Allergens and Allergy. Advances in Immunology, 2018, 138, 195-256.	2.2	81
15	MUC18/MCAM (CD146), an activation antigen of human T lymphocytes. Journal of Immunology, 1997, 158, 2107-15.	0.8	81
16	Immunological imprint of COVID-19 on human peripheral blood leukocyte populations. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 751-765.	5.7	71
17	The IL-10/STAT3 axis: Contributions to immune tolerance by thymus and peripherally derived regulatory T cells. European Journal of Immunology, 2017, 47, 1256-1265.	2.9	70
18	Association between IgE response against Bet v I, the major allergen of Birch Pollen, and HLA-DRB alleles. Human Immunology, 1992, 33, 259-265.	2.4	67

#	ARTICLE	IF	CITATIONS
19	Past, present, and future of allergen immunotherapy vaccines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 131-149.	5.7	66
20	T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. <i>Journal of Immunological Methods</i> , 2010, 362, 131-141.	1.4	65
21	Serum amyloid A is a soluble pattern recognition receptor that drives type 2 immunity. <i>Nature Immunology</i> , 2020, 21, 756-765.	14.5	63
22	CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 290-299.e4.	2.9	62
23	Direct stimulation of T lymphocytes by immunosomes: Virus-like particles decorated with T cell receptor/CD3 ligands plus costimulatory molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13144-13149.	7.1	54
24	Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis. <i>Nature Communications</i> , 2019, 10, 3106.	12.8	48
25	A cellular platform for the evaluation of immune checkpoint molecules. <i>Oncotarget</i> , 2017, 8, 64892-64906.	1.8	48
26	CD19+CD21low B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 250-258.	2.0	47
27	No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. <i>European Journal of Immunology</i> , 2006, 36, 1104-1113.	2.9	45
28	Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 230-242.	5.7	45
29	Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 878-883.	5.7	39
30	Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation. <i>Scientific Reports</i> , 2017, 7, 42191.	3.3	36
31	General Strategy for Decoration of Enveloped Viruses with Functionally Active Lipid-Modified Cytokines. <i>Journal of Virology</i> , 2007, 81, 8666-8676.	3.4	35
32	Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 64-71.	2.9	31
33	Prevention of allergy by virus-like nanoparticles (<sc>VNP</sc>) delivering shielded versions of major allergens in a humanized murine allergy model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 246-260.	5.7	31
34	On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy). <i>International Archives of Allergy and Immunology</i> , 2016, 170, 211-233.	2.1	30
35	Bet v 1-specific T-cell receptor/forkhead box protein 3 transgenic T cells suppress Bet v 1-specific T-cell effector function in an activation-dependent manner. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 238-245.e3.	2.9	29
36	Expression of I α 2-microglobulin-free HLA class I chains on activated T cells requires internalization of HLA class I heterodimers. <i>Immunology</i> , 1996, 88, 104-109.	4.4	27

#	ARTICLE	IF	CITATIONS
37	Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 121-128.	2.9	27
38	Genetic restriction of antigen-presentation dictates allergic sensitization and disease in humanized mice. <i>EBioMedicine</i> , 2018, 31, 66-78.	6.1	24
39	The soluble pool of beta 2-microglobulin free HLA class I alpha-chains. Qualitative and quantitative characterization. <i>Journal of Immunology</i> , 1993, 151, 2613-22.	0.8	24
40	SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	24
41	Creation of an engineered APC system to explore and optimize the presentation of immunodominant peptides of major allergens. <i>Scientific Reports</i> , 2016, 6, 31580.	3.3	22
42	The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4+ T cells and inhibits c-Myc activation. <i>Journal of Leukocyte Biology</i> , 2016, 99, 583-594.	3.3	22
43	Distinct epitope structures of defensin-like proteins linked to proline-rich regions give rise to differences in their allergenic activity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 431-441.	5.7	22
44	Expression of LA45 reactive β 2-microglobulin free HLA Class I α -chains on activated T cells is regulated by internalization, constitutive and protein kinase C inducible release. <i>Tissue Antigens</i> , 1996, 48, 15-21.	1.0	21
45	Characterization of HLA Class II/Peptide-TCR Interactions of the Immunodominant T Cell Epitope in Art v 1, the Major Mugwort Pollen Allergen. <i>Journal of Immunology</i> , 2008, 181, 3636-3642.	0.8	21
46	STAT3 governs hyporesponsiveness and granzyme B-dependent suppressive capacity in human CD4 + T cells. <i>FASEB Journal</i> , 2015, 29, 759-771.	0.5	21
47	Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?. <i>Frontiers in Immunology</i> , 2020, 11, 1368.	4.8	21
48	Soluble pattern recognition molecules: Guardians and regulators of homeostasis at airway mucosal surfaces. <i>European Journal of Immunology</i> , 2020, 50, 624-642.	2.9	21
49	<i>MEF2C</i> -dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with <i>CDKN1B</i> deletions and a poor response to glucocorticoid therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2895-2904.	1.3	19
50	Blocking antibodies induced by allergen-specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 851-861.	5.7	19
51	The making and function of CAR cells. <i>Immunology Letters</i> , 2019, 212, 53-69.	2.5	19
52	Human TCR Transgenic Bet v 1-Specific Th1 Cells Suppress the Effector Function of Bet v 1-Specific Th2 Cells. <i>Journal of Immunology</i> , 2011, 187, 4077-4087.	0.8	18
53	<i>NI</i> : a novel canine mastocytoma model for studying drug resistance and <i>gER</i> -dependent mast cell activation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 858-868.	5.7	18
54	Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor-ligand interactions. <i>FASEB Journal</i> , 2010, 24, 1572-1582.	0.5	17

#	ARTICLE	IF	CITATIONS
55	Germline biallelic PIK3CG mutations in a multifaceted immunodeficiency with immune dysregulation. <i>Haematologica</i> , 2020, 105, e488.	3.5	17
56	Lipid Rafts, Pseudotyping, and Virus-Like Particles: Relevance of a Novel, Configurable, and Modular Antigen-Presenting Platform. <i>International Archives of Allergy and Immunology</i> , 2011, 154, 89-110.	2.1	16
57	Vaccine based on folded receptor binding domainâ€PreS fusion protein with potential to induce sterilizing immunity to SARSâ€CoVâ€2 variants. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2431-2445.	5.7	16
58	National Institutes of Healthâ€Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution. <i>Frontiers in Immunology</i> , 2019, 10, 1879.	4.8	14
59	Omicron: A SARSâ€CoVâ€2 variant of real concern. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1616-1620.	5.7	14
60	Fluorosomes: Fluorescent Virus-Like Nanoparticles that Represent a Convenient Tool to Visualize Receptor-Ligand Interactions. <i>Sensors</i> , 2013, 13, 8722-8749.	3.8	13
61	Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 145-149.	1.5	13
62	Murine models for mucosal tolerance in allergy. <i>Seminars in Immunology</i> , 2017, 30, 12-27.	5.6	12
63	Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro. <i>Frontiers in Immunology</i> , 2019, 10, 1790.	4.8	12
64	All the small things: How virusâ€like particles and liposomes modulate allergic immune responses. <i>European Journal of Immunology</i> , 2020, 50, 17-32.	2.9	12
65	Allergen-specific IgE levels and the ability of IgE-allergen complexes to cross-link determine the extent of CD23-mediated T-cell activation. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 958-967.e5.	2.9	11
66	Attenuation of canonical NFâ€kB signaling maintains function and stability of human Treg. <i>FEBS Journal</i> , 2021, 288, 640-662.	4.7	9
67	The energy sensor AMPK orchestrates metabolic and translational adaptation in expanding T helper cells. <i>FASEB Journal</i> , 2021, 35, e21217.	0.5	9
68	Associations between specific IgE sensitization to 26 respiratory allergen molecules and HLA class II alleles in the EGEA cohort. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2575-2586.	5.7	9
69	Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients. <i>ACS Synthetic Biology</i> , 2021, 10, 1184-1198.	3.8	9
70	Years in Review: Recent Progress in Cellular Allergology. <i>International Archives of Allergy and Immunology</i> , 2016, 169, 1-12.	2.1	8
71	Allergen alters ILâ€2/ILâ€2â€based Treg expansion but not tolerance induction in an allergenâ€specific mouse model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1618-1629.	5.7	8
72	Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1. <i>Frontiers in Immunology</i> , 2021, 12, 744544.	4.8	8

#	ARTICLE	IF	CITATIONS
73	Unreported Missense Mutation in the Dimerization Domain of ADA2 Leads to ADA2 Deficiency Associated with Severe Oral Ulcers and Neutropenia in a Female Somalian Patient—Addendum to the Genotype-Phenotype Puzzle. <i>Journal of Clinical Immunology</i> , 2020, 40, 223-226.	3.8	7
74	Combined assessment of Sâ€•and Nâ€•specific <sc>IL</sc>â€•2 and <sc>IL</sc>â€•13 secretion and <sc>CD69</sc> neoâ€•expression for discrimination of postâ€•infection and postâ€•vaccination cellular <sc>SARSâ€•CoV</sc>â€•2â€•specific immune response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3408-3425.	5.7	7
75	Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib. <i>Blood</i> , 2007, 110, 1541-1541.	1.4	6
76	Tick-Borne Encephalitis Specific Lymphocyte Response after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Humoral Immunity after Vaccination. <i>Vaccines</i> , 2021, 9, 908.	4.4	5
77	Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.. <i>Blood</i> , 2006, 108, 526-526.	1.4	5
78	Lack of Induction of RBD-Specific Neutralizing Antibodies despite Repeated Heterologous SARS-CoV-2 Vaccination Leading to Seroconversion and Establishment of T Cell-Specific Memory in a Patient in Remission of Multiple Myeloma. <i>Vaccines</i> , 2022, 10, 374.	4.4	5
79	Characterization of the antibody response to SARSâ€•CoVâ€•2 in a mildly affected pediatric population. <i>Pediatric Allergy and Immunology</i> , 2022, 33, e13737.	2.6	5
80	CD8+ T Cell Fate and Function Influenced by Antigen-Specific Virus-Like Nanoparticles Co-Expressing Membrane Tethered IL-2. <i>PLoS ONE</i> , 2015, 10, e0126034.	2.5	3
81	Pharmacological targeting of allergen-specific T lymphocytes. <i>Immunology Letters</i> , 2017, 189, 27-39.	2.5	3
82	The Hsp32/HO-1-targeted drug SMA-ZnPP counteracts the proliferation and viability of neoplastic cells in solid tumors and hematologic neoplasms. <i>Journal of Clinical Oncology</i> , 2007, 25, 14122-14122.	1.6	3
83	Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.. <i>Blood</i> , 2005, 106, 3518-3518.	1.4	2
84	Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.. <i>Blood</i> , 2004, 104, 2544-2544.	1.4	2
85	Editorial: Challenges in Vaccinology. <i>Frontiers in Immunology</i> , 2020, 11, 632537.	4.8	2
86	Art v 1 IgE epitopes of patients and humanized mice are conformational. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 920-930.	2.9	2
87	The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells.. <i>Blood</i> , 2004, 104, 1986-1986.	1.4	1
88	Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107.. <i>Blood</i> , 2005, 106, 3516-3516.	1.4	1
89	Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.. <i>Blood</i> , 2006, 108, 1901-1901.	1.4	1
90	The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.. <i>Blood</i> , 2007, 110, 1046-1046.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFR β .. Blood, 2007, 110, 3559-3559.	1.4	1
92	Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells.. Blood, 2009, 114, 1717-1717.	1.4	1
93	Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML.. Blood, 2004, 104, 2972-2972.	1.4	0
94	BCR/ABL Induces Expression of Histidine Decarboxylase and Synthesis of Histamine in CML Cells.. Blood, 2005, 106, 4835-4835.	1.4	0
95	Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors.. Blood, 2005, 106, 1987-1987.	1.4	0
96	Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.. Blood, 2006, 108, 4323-4323.	1.4	0
97	Circulating B-Lymphocyte Subpopulations as Novel Biomarker for Measuring Activity of Chronic Graft-Versus-Host Disease.. Blood, 2006, 108, 2881-2881.	1.4	0
98	The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.. Blood, 2006, 108, 1437-1437.	1.4	0
99	The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.. Blood, 2007, 110, 3554-3554.	1.4	0
100	Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).. Blood, 2008, 112, 1616-1616.	1.4	0
101	Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax $\text{\textcircled{R}}$) on Growth and Viability of Canine and Human Neoplastic Mast Cells. Blood, 2008, 112, 861-861.	1.4	0
102	Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells. Blood, 2008, 112, 3195-3195.	1.4	0
103	Assessment of the Potential of Immature CD19+CD21- B-Lymphocytes to Predict Response to Various Systemic Therapies in Chronic Graft-Versus-Host Disease.. Blood, 2009, 114, 2226-2226.	1.4	0
104	The Multi-Kinase/ABL Inhibitor R763/AS703569 Induces DNA Endoreduplication and Apoptosis In Imatinib-Resistant CML Cells and Synergizes with Nilotinib, Dasatinib, and the Plk-1 Inhibitor BI 2536, In Producing Growth Inhibition.. Blood, 2010, 116, 3394-3394.	1.4	0
105	Nilotinib and Dasatinib Produce Synergistic Growth-Inhibitory Effects In Imatinib-Resistant CML Cells, Including Subclones Bearing the Multi-Resistant BCR/ABL Mutant T315I. Blood, 2010, 116, 2280-2280.	1.4	0
106	The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML. Blood, 2011, 118, 4414-4414.	1.4	0
107	5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells,. Blood, 2011, 118, 3457-3457.	1.4	0
108	Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra. Blood, 2012, 120, 1760-1760.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Value of Autoantibody Expression During Long-Term Follow-Up in Paediatric ALL Patients After Allogeneic Haematopoietic Stem Cell Transplantation. <i>Frontiers in Pediatrics</i> , 2021, 9, 788360.	1.9	0